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Objective. To evaluate the plasma and aqueous humor disposition of prednisolone after oral administration in cats.Methods. Six cats
were administered with a single oral dose of prednisolone (10mg). Blood and aqueous humor samples were serially collected after
drug administration. Prednisolone concentrations in plasma and aqueous humor were measured at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0,
and 5.0 h after administration by a high-performance liquid chromatographic analytical method developed and validated for this
purpose. Results. Mean ± standard error (SE) of maximum plasma prednisolone concentration (300.8 ± 67.3 ng/mL) was reached
at 1 h after administration. Prednisolone was distributed to the aqueous humor reaching a mean peak concentration of 100.9 ±
25.5 ng/mL at 1.25 h after administration.Themean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng∗h/mL
and 378.8 ± 64.9 ng∗h/mL, respectively. A high AUCaqueous humor/AUCplasma ratio was observed (0.68 ± 0.13).Themean half-life time
of elimination in plasma and aqueous humor was 0.87 ± 0.16 h and 2.25 ± 0.44 h, respectively. Clinical Significance. The observed
high ratio between aqueous humor and plasma prednisolone concentrations indicates that extensive penetration of prednisolone
to the anterior segment of the eye may occur. This is the first step that contributes to the optimization of the pharmacological
therapeutics for the clinical treatment of uveitis.
1. Introduction
Uveitis is a frequent ophthalmic disorder in domestic cats
commonly associated with perforating or blunt traumas,
systemic diseases, neoplasia, intraocular surgery, and lens-
induced uveitis [1]. Currently, the treatment of feline uveitis
of any etiology is based on topical and/or systemic corti-
costeroid or anti-inflammatory nonsteroidal agents [1, 2].
Despite the fact that the use of potent anti-inflammatory
drugs carries the risk of side effects, corticosteroids remain
themainstay of the prevention and treatment ofmany painful
and potentially blinding ocular diseases in different species
[3]. Prednisolone is a synthetic adrenocortical steroid used
primarily due to its anti-inflammatory activity in several
diseases [4]. In addition, due to the potential antiangiogenic,
antiedematous, antiapoptotic, and antiproliferative effects of
prednisolone, this steroid gained wide use in the treatment of
both anterior and posterior ocular segment diseases [5].
Although topical administration of prednisolone is
widely used in the treatment of anterior uveitis, oral adminis-
tration is also used in traumatic, after intraocular surgery, and
neoplastic uveitis [1]. However, there is limited information
about ocular prednisolone disposition after its oral adminis-
tration in small species including the cat.
Previous studies on plasma pharmacokinetics of pred-
nisolone have been performed in humans, rats, rabbits,
cows, sheep, horses, dogs, and cats [6–13], but there are no
reports about ocular disposition of the corticoid after oral
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administration in any of those species. In order to character-
ize the pharmacokinetics of prednisolone in different biolog-
ical matrices, an analytical technique needs to be developed
to obtain precise and accurate results. Different techniques
were previously reported in the literature to estimate steroids
concentrations in biological samples [14–20]. However, the
methodologies to measure prednisolone in aqueous humor
are limited, and there are no previous reports about a
specific high-performance liquid chromatographic (HPLC)
analytical method to quantify prednisolone in plasma and/or
aqueous humor of cats.
Thus, the main goal of the current work was to evalu-
ate the systemic kinetic behaviour of prednisolone and its
distribution to aqueous humor after oral administration to
cats. The work included the development and validation of
an analytical HPLCmethodology to quantify prednisolone in
cat plasma and aqueous humor.
2. Materials and Methods
2.1. Animals. Six intact young European short-hair male cats
with an average ± standard deviation (SD) weight of 4.2 ±
0.5 kg, obtained from the research colony of Facultad de
Ciencias Veterinarias (UNCPBA), were used in the present
study. Animals were housed individually in a temperature-
and light-controlled environment (fluorescent lights were
automatically turned on and off every 12 h) and fed with a
balanced diet and water ad libitum. They were acclimated to
human contact for 4 to 6 weeks prior to the study. Previous to
their inclusion in the study it was assured that the animals
were in healthy physical and ocular condition, through-
out physical and ocular examination. Ocular examination
included Schirmer tear test measurements (Schirmer tear
test strips, Schering-Plough Animal Health Corp., Union,
New Jersey, USA), fluorescein staining (Love Sudamericana
Laboratory, Argentina), applanation tonometry (Tono-Pen
XL, Mentor, Norwell, MA, USA), slit lamp biomicroscopy
(HLS 150, Heine Optotechnik, Herrsching, Germany), direct
(Heine Beta 200, Heine Optotechnik, Herrsching, Germany)
and indirect (20-D lens, Ocular Instruments, Bellevue,Wash;
Heine Omega 150, Heine Optotechnik, Herrsching, Ger-
many) ophthalmoscopies. During the sampling period and
the following 24 h, the animals were evaluated for aqueous
flare and others signs of uveitis by slit lamp biomicroscopy.
The cats did not receive any medications containing pred-
nisone or prednisolone prior to the study (including topical
preparations). All animal procedures were conducted in strict
accordance with the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Vision Research and Animal Welfare Policy
(Act 087/02, Facultad de Ciencias Veterinarias, UNCPBA,
http://www.vet.unicen.edu.ar).
2.2. Experimental Administration and Sample Collection.
Immediately after oral administration of 10mg of pred-
nisolone (Prednisolona Syntex, Syntex S.A., Argentina), cats
were anesthetized using I.M. ketamine (7mg/kg)-xylazine
(1mg/kg) and maintained with I.V. ketamine (3.5mg/kg)-
xylazine (0.1mg/kg) administered 5minutes previous to each
sample extraction. Blood samples (2mL) were taken through
preplaced cephalic antebrachial intravenous catheters before
and at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, and 5.0 h after pred-
nisolone administration. Blood samples were centrifuged at
2000×g for 15min, and the separated plasma was transferred
to plastic tubes. Aqueous humor samples were obtained
alternating between each eye by paracentesis of the anterior
chamber at the same blood sampling times. Aqueous humor
samples (450𝜇L) were collected slowly using a disposable
1mL syringe with a 25 gauge needle, with the minimal vac-
uum needed to obtain the samples, as previously described
[21]. Both plasma and aqueous humor samples were stored at
−20∘C until HPLC analysis.
2.3. Sample Preparation. All plasma and aqueous humor
samples were vortexed, and aliquots of 300 𝜇L of plasma
or 450𝜇L of aqueous humor were placed into glass tubes.
Plasma and aqueous humor samples were spiked with 40 𝜇L
and 45 𝜇L of the internal standard (dexamethasone 1 𝜇g/mL),
respectively. Prednisolone was extracted by the addition of
1mL of ethyl acetate under a high speed vortexing shaker over
10min. After centrifugation at 2500×g for 10min (4∘C) to
allow phase separation, the clear supernatant was transferred
to a 5mL glass tube. This volume was evaporated (45∘C) to
dryness in a vacuum concentrator and then reconstituted
with 300 𝜇L of mobile phase.
2.4. HPLC Analysis. Experimental and fortified plasma and
aqueous humor samples were analysed for prednisolone by
HPLC. After extraction, 100 𝜇L aliquots were injected in a
Shimadzu Chromatography system (Shimadzu Corporation,
Kyoto, Japan). The equipment was composed of two LC-
10AS solvent pumps, an automatic sample injector (SIL-10A)
with a 100 𝜇L loop, an ultraviolet visible spectrophotometer
detector (UV) (SPD-10A), a column oven (Eppendorf TC-
45, Eppendorf, Madison, WI, USA) set at 30∘C, and a
CBM-10A data integrator. Data and chromatograms were
collected and analysed using the Class LC10 software (SPD-
10A, Shimadzu Corporation, Kyoto, Japan). A C18 reversed-
phase column (Kromasil, Eka Chemicals AB, NY, USA) of
250mm × 4.6mm with 5 𝜇m particle size was used for
separation. Elution from the stationary phase was carried
out at a flow rate of 1.2mL/min using acetonitrile and water
(36 : 64) in isocratic mode as mobile phase during 11min.
The detector was set at 254 nm. A complete validation of the
analytical procedures for the extraction and quantification
of prednisolone in plasma and aqueous humor was per-
formed before starting the analysis of the biological samples.
Recovery of prednisolone was estimated by the comparison
of the peak areas from spiked plasma and aqueous humor
samples with the areas resulting from direct injections of
standards in mobile phase. Precision (intra- and inter-assay)
was determined by analyzing replicates of eachmatrix sample
enriched with prednisolone standard to achieve 50, 100 and
200 ng/mL for plasma and 10, 50 and 100 ng/mL for aqueous
humor. The intraday and interday precision and accuracy
of the method were evaluated by coefficient of variation
(CV) and relative error (RE; RE = 100 × [(predicted concen-
tration − nominal concentration)/nominal concentration]).
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The theoretical limit of quantification (LOQ) for pred-
nisolone in plasma and aqueous humor were determined
comparing the signal of zero samples of the different bio-
logical matrices fortified with the internal standard and
measurement of the baseline noise at the retention time
of prednisolone. The mean baseline noise plus six standard
deviationswas defined as the theoretical LOQ.The robustness
was evaluated on the retention time (𝑡
𝑅
), recovery and
repeatability of the method (% CV) by deliberate variations
of the column temperature (30 and 35∘C), flow rate (1 and
1.2mL/min), and brand columns (Kromasil, Eka Chemicals
AB, NY, USA and Phenomenex, CA, USA).
2.5. Pharmacokinetic Analysis. Thepharmacokinetic analysis
of prednisolone after oral administration to cats was car-
ried out using the program PK Solution (Summit Research
Services, Ashland, USA). Pharmacokinetic analysis of the
experimental data was performed by a noncompartmental
analysis. The following equation [22] was used to describe
the biexponential concentration versus time curves for pred-
nisolone in plasma and aqueous humor for each cat after the
oral administration: 𝐶
𝑝
= 𝐵𝑒
−𝛽𝑡
−𝐴𝑒
−𝑎𝑡, where 𝐶
𝑝
= concen-
tration (ng/mL) in plasma or aqueous humor at time 𝑡 after
administration, 𝐴 is concentration at time zero extrapolated
from the absorption phase (ng/mL), 𝐵 is concentration at
time zero extrapolated from the elimination phase (ng/mL), 𝑒
is base of the natural logarithm, 𝛽 is terminal slope (h−1), and
𝑎 is the slope obtained by feathering which represents the first
order absorption rate constant (𝑘abs) (h
−1). No lag time was
observed for plasma or aqueous humor pharmacokinetics.
The maximum concentration (𝐶max) was obtained from the
observed data. The area under the concentration (AUC)
versus time curves was calculated by the trapezoidal rule
[23].The absorption (𝑇
1/2abs) and the elimination (𝑇1/2el) half-
lives were calculated as ln 2/𝑘abs and ln 2/𝛽, respectively.
Statistical moment theory was applied to calculate the mean
residence time (MRT) in plasma and aqueous humor as
follows [23]: MRT = AUMC/AUC, where AUC was defined
previously and AUMC is the area under the curve for the first
moment, obtained by the product of time and the plasma or
aqueous humor drug concentrations versus time from zero to
infinity [24].
2.6. Statistical Data Analysis. The pharmacokinetic parame-
ters are reported as mean ± SE and the concentration data as
mean ± SD. Student’s 𝑡-test was used to compare parameters.
A value of 𝑃 < 0.05 was considered statistically significant.
3. Results
Prednisolone plasma and aqueous humor concentrations
after oral administration of 10mg of prednisolone to cats were
quantified using the analytical assay developed in the present
work. The calibration curves for prednisolone were linear
in the range of 25–500 and 5–200 ng/mL (𝑟2 > 0.993 and
0.999) for plasma and aqueous humor, respectively.The linear
regression was further supported by a homogeneous distri-
bution of residuals and homoscedasticity of the variance.
Table 1: HPLC analytical validation.
Chromatographic parameter Plasma Aqueous humor
Absolute recovery range (%) 72–78 89–93
Intraday precision (%CV) 3.2–5.5 3.3–4
Interday precision (%CV) 4.2–7.6 2.3–11.1
Interday accuracy (%RE) 5.1–13.1 7.0–17.2
LOD (ng/mL) 4.3 1.3
LOQ (ng/mL) 25 5
Precision LOQ (%CV) 12.4 5.8
Stability (%CV) 3.8–4.5 0.9–4.6
CV: coefficient of variation; LOD: limit of detection; LOQ: limit of quan-
tification; RE (relative error) = 100 × [(predicted concentration − nominal
concentration)/nominal concentration].
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Figure 1: Mean ± SD prednisolone plasma and aqueous humor
concentration profiles versus time obtained after its oral administra-
tion (10mg) to cats. TL: therapeutic level concentration is reported
as sufficient to suppress inflammation and minimise side effects in
humans (25 ngmL−1).
The theoretical LOQ of the method was 25 and 5 ng/mL
for plasma and aqueous humor, respectively. The method
exhibited a high degree of intraday and interday precision
and accuracy as demonstrated by low CV and RE. The
values of the main parameters determined in the validation
methodology are shown in Table 1. Deliberate variation of the
method conditions had no significant effect on assay data or
on chromatographic performance, indicating the robustness
of method and its suitability for routine use and transference
to other laboratories.
Prednisolone concentrations were detected in both
plasma and aqueous humor in all sampling periods after
oral administration of 10mg per cats. Mean plasma and
aqueous humor concentration profiles versus time are shown
in Figure 1. Prednisolone was detectable in plasma from
0.25 up to 5 h after administration. The mean ± SD plasma
concentration at the first sampling timewas 58.0±96.8ng/mL
4 BioMed Research International
Table 2: Plasma and aqueous humor pharmacokinetic parameters
for prednisolone after a single oral administration (10mg) to cats.
Pharmacokinetic parameter Plasma Aqueous humor
Mean SE Mean SE
𝑇
1/2abs (h) 0.37 0.07 0.55 0.09
𝐶max (ng/mL) 300.8 67.3 100.9 25.5
𝑇max (h) 1 0.25 2.25 0.31
MRT (h) 2.24 0.42 4.39 0.64
𝑇
1/2el (h) 0.87 0.16 2.25 0.44
AUC (ng⋅h/mL) 553.3 120.0 378.8 64.9
𝑇
1/2abs: absorption half-life; 𝐶max: maximum concentration; 𝑇max: time to
maximum concentration; MRT: mean residence time; 𝑇
1/2el: elimination
half-life; SE: standard error; AUC: area under the concentration—time curve.
and reached a mean ± SE maximum (𝐶max) level of 300.8 ±
67.3 ng/mL at 1 ± 0.25 h (𝑇max, ±SE). In addition, the lowest
mean ± SD plasma concentration of 22.0 ± 26.6 ng/mL was
observed after 5 hours of drug administration. In aqueous
humor, the concentration measured at 0.25 h after admin-
istration was lower than the LOQ, and the mean 𝐶max was
100.9 ± 25.5 ng/mL at 1.25 ± 0.30 h (𝑇max). Prednisolone
concentration was higher in plasma than in aqueous humor
up to 2 hours after drug administration, and thereafter
both concentrations were similar as shown in Figure 1. At
the last sampling time (5 h), the concentration in aqueous
humor was higher than that observed in plasma. Plasma and
aqueous humor calculated pharmacokinetic parameters are
summarized in Table 2.The prednisolone absorption process
to the systemic circulation was fast with a mean absorption
half-life (𝑇
1/2abs, ±SE) of 0.37 ± 0.07 h. The mean half-life
time of elimination (𝑇
1/2el) in plasma was 0.87 ± 0.16 h, and
meanwhile the prednisolone 𝑇
1/2el in the aqueous humor
was longer (2.25 ± 0.44 h). Prednisolone plasma and aqueous
humor exposure, represented by the AUC ± SE, was 553.3 ±
120.0 ng∗h/mL and 378.8 ± 64.9 ng∗h/mL, respectively. The
mean ± SE AUCaqueous humor/AUCplasma ratio was 0.68 ± 0.13.
4. Discussion
In the present study, we developed an analytical assay for
quantification of prednisolone in aqueous humor and plasma
and characterized prednisolone pharmacokinetics in plasma
and aqueous humor after oral administration to cats. This is
the first study to evaluate the disposition of prednisolone in
aqueous humor after oral administration.
After systemic administration, once absorbed, drug
molecules are distributed throughout the body in the circu-
lating blood, and they must diffuse into the target tissues to
exert the pharmacological effect. The concentration attained
at the desired target tissue depends on the delivery process of
the drug to the tissues and the ability of the drug to penetrate
capillary endothelium and diffuse across cell membranes
[25], where factors such as lipophilicity and the binding of
the drug to plasma proteins and other tissue components
play a critical role [26]. Therefore, the tissue distribution
process varies widely for different drug molecules and has to
be studied in each case [27].
After oral prednisolone administration to cats, we
observed that plasma and aqueous humor concentrations
were quantifiable at 0.25 h, demonstrating that both pred-
nisolone absorption and aqueous humor distribution pro-
cesses were fast. In addition, it has been previously reported
that a prednisolone concentration of 25 ng/mL has to be
attained in human aqueous humor in order to suppress
inflammation [28]. Currently, there is no information about
the aqueous humor level that needs to be attained to obtain an
anti-inflammatory response in cats. Apart from this limita-
tion, if we considered the level reported in humans, we could
expect that the prednisolone aqueous humor concentrations
attained in the present work should be pharmacologically
active for at least 5 hours after the oral administration of 10mg
of prednisolone in cats (Figure 1).
In the current work, the maximal concentration of
prednisolone (𝐶max) in plasma was attained at 1 h and
reached a mean ± SE value of 300.8 ± 67.3 ng/mL, and
the mean prednisolone plasma exposure, represented by the
AUC, was 553.3 ng∗h/mL. While higher systemic exposure
of prednisolone was previously reported in cats [13], the
rate of drug absorption and elimination was comparable to
our present results. A feasible explanation for the different
results could be attributed to differences in animal weight
and, thus, in volume of distribution. Besides, plasma 𝐶max
values that were obtained after 10mg oral prednisolone in
rats (863 ng/mL) were higher than the values observed in the
present experiment in cats. This is probably due to the lower
volume of distribution of the rat [7].
In the present study, we reported plasma half-life time
of elimination of 0.66 h, comparable to previous reports
in cats [13]. On the contrary, longer 𝑇
1/2el values (around
3 h) were reported after oral prednisolone in humans [6,
29]. When corrected for dose and considering the volume
of distribution, the systemic exposure in human (AUC) is
higher than that in cats probably because the 3-fold difference
in 𝑇
1/2el between species. The lower plasma 𝐶max and AUC
and the shorter prednisolone 𝑇
1/2el in cats with respect
to humans may be associated with a higher metabolism
and/or elimination rate or a less protein-bound prednisolone
(transcortin) in this species. With important interspecies
variations, prednisolone protein binding may affect pharma-
cokinetic parameters such as drug concentration, volume of
distribution, and elimination rate which could explain the
differences in distribution process and volume between cats
and humans [30].
The aqueous humor drug exposure to prednisolone was
lower than that calculated for plasma (AUC = 553.3 ±
120 ng∗h/mL) leading to anAUCaqueous humor/AUCplasma ratio
of 0.68 ± 0.13, indicating an extensive prednisolone distribu-
tion into the aqueous humor after systemic administration to
cats. Interestingly, aqueous humor 𝑇
1/2el and mean residence
time were much longer than those observed in plasma (𝑃 <
0.01), indicating a longer residence in the eye.
According to the results previously reported for dexam-
ethasone, another corticosteroid widely used for uveitis treat-
ment, after a single oral dose of 7.5mg the drug penetrates
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into the posterior segment in humans and the ratio mean
𝐶max vitreous/𝐶max plasma was approximately equal to 0.084.
Assuming that this ratio is comparable between dexametha-
sone and prednisolone and similar between humans and
cats, based on the plasma 𝐶max obtained in the present
study (300.8 ± 67.3 ng/mL), the vitreous levels should be
about 25 ng/mL. Hence, we suggest that a therapeutic drug
level would be attained in the vitreous of our animal model
after 10mg of prednisolone [31]. If we considered this ratio,
we can suppose that the vitreous humor level after oral
administration of prednisolone should be lower than that
in aqueous humor. Thus, assuming that the rate constant of
drug transfer from the plasma to the vitreous is comparable
between humans and cats, and that the therapeutic level
in cats is similar to that in humans (25 ng/mL) [28], then
based on the plasma 𝐶max obtained in the present study
(300.8 ± 67.3 ng/mL) we could hypothesize that a therapeutic
drug level would be attained in the vitreous of our animal
model after 10mg of prednisolone. However, the interval of
time during which prednisolone vitreous concentrations are
higher than 25 ng/mL has to be determined.
Anaesthesia for short periods was necessary to obtain the
aqueous humor samples. For this purpose, similar to previous
works, the animals were administered at each sampling time
with ketamine and xylazine, since no interaction between
prednisolone and these anaesthetic drugs has been observed
[32, 33]. As described previously, under our experimental
conditions, a single paracentesis does not induce ocular
inflammation in cats [21]. Although four repetitive paracen-
teses were performed in this study, with a minimal interval of
45 minutes and a maximal of 120 minutes between samples,
we did not observe any clinical signs of blood ocular barriers
(BOB) breakdown during the sampling period or during the
next 24 h, when the cats were examined before reposition to
the research colony. It could be possible that the prednisolone
directly reduced PGE synthesis and increased vascular sta-
bility avoiding BOB breakdown [34]. However, subclinical
BOB breakdown could have occurred during sampling in the
present experiment, and this could have increased slightly
the aqueous humor drug levels. To avoid this situation, a
microdialysis sampling technique is being developed to be
used in future studies of prednisolone disposition in the eye.
Although the low content of aqueous humor proteins
could result in a greater fraction of free prednisolone with
respect to the plasma content, the BOB subclinical break-
down may lead to increased transcortin levels over time
compensating the physiologic low levels of proteins.
In conclusion, the simple, precise, and accurate method
developed and validated to quantify prednisolone in
plasma and aqueous humor allowed us to obtain novel
pharmacology-based information on the distribution of
prednisolone in cats. This is a useful first step to evaluate the
potential of prednisolone as an anti-inflammatory systemic
drug for use in feline anterior uveitis. The pharmacokinetic
characterization of prednisolone in plasma and aqueous
humor after oral administration to cats indicates that the
drug penetrates into the anterior chamber of the eye. Follow-
up studies to characterize the pattern of distribution in the
vitreous humor and to determine the anti-inflammatory
levels of prednisolone are required to further evaluate the
potential of this drug as an anti-inflammatory drug in the
treatment of uveitis.
Conflict of Interests
The authors confirm that there is no known conflict of
interests associated with this publication and that there has
been no significant financial support for this work that could
have influenced its outcome. They also confirm that they
do not have a direct financial relation with any commercial
identity mentioned in their paper that might lead to a conflict
of interests for any of the authors. They further confirm that
any aspect of the work covered in this study that has involved
experimental animals has been conducted with the ethical
approval of all relevant bodies.
Acknowledgments
This work was partially supported by Consejo Nacional
de Investigaciones Cient´ıficas y Te´cnicas (CONICET)
and Agencia Nacional de Promocio´n Cient´ıfica y Te´cnica
(ANPCyT), both from Argentina.
References
[1] J. Stiles and W. M. Townsend, “Feline ophthalmology,” in
Veterinary Ophthalmology, K. N. Gelatt, Ed., pp. 1117–1127,
Blackwell, Ames, Iowa, USA, 4th edition, 2007.
[2] W. M. Townsend, “Canine and feline uveitis,” Veterinary Clinics
of NorthAmerica—Small Animal Practice, vol. 38, no. 2, pp. 323–
346, 2008.
[3] B. J. Holmberg and D. J. Maggs, “The use of corticosteroids
to treat ocular inflammation,” Veterinary Clinics of North
America—Small Animal Practice, vol. 34, no. 3, pp. 693–705,
2004.
[4] F. L. S. Tse and P. G. Welling, “Prednisolone bioavailability in
the dog,” Journal of Pharmaceutical Sciences, vol. 66, no. 12, pp.
1751–1754, 1977.
[5] M. A. Cunningham, J. L. Edelman, and S. Kaushal, “Intravitreal
steroids for macular edema: the past, the present, and the
future,” Survey of Ophthalmology, vol. 53, no. 2, pp. 139–149,
2008.
[6] K.-H. Lee, “Bioavailability of oral prednisolone,” Seoul Journal
of Medicine, vol. 32, no. 3, pp. 131–137, 1991.
[7] A. Isowaki, A. Ohtori, Y. Matsuo, and K. Tojo, “Drug delivery to
the eye with a transdermal therapeutic system,” Biological and
Pharmaceutical Bulletin, vol. 26, no. 1, pp. 69–72, 2003.
[8] J. D. Unadkat and M. Rowland, “Pharmacokinetics of pred-
nisone and prednisolone at steady state in the rabbit,” Drug
Metabolism and Disposition, vol. 13, no. 4, pp. 503–509, 1985.
[9] P. L. Toutain, G. D. Koritz, and M. Alvinerie, “Prednisolone
succinate and prednisolone acetate in cattle: pharmacokinetics
and action on the adrenal gland,”American Journal of Veterinary
Research, vol. 46, no. 3, pp. 719–725, 1985.
[10] M. Alvinerie, G. Houin, and P. L. Toutain, “Prednisolone
binding to plasma proteins in domestic species,” Journal of
Pharmaceutical Sciences, vol. 77, no. 11, pp. 937–938, 1988.
[11] P. L. Toutain, R. A. Brandon, and H. De Pomyers, “Dexam-
ethasone and prednisolone in the horse: pharmacokinetics and
6 BioMed Research International
action on the adrenal gland,” American Journal of Veterinary
Research, vol. 45, no. 9, pp. 1750–1756, 1984.
[12] B. M. Frey, F. J. Frey, and N. H. G. Holford, “Prednisolone phar-
macodynamics assessed by inhibition of the mixed lymphocyte
reaction,” Transplantation, vol. 33, no. 6, pp. 578–584, 1982.
[13] C.A.Graham-Mize andE. J. Rosser, “Bioavailability and activity
of prednisone and prednisolone in the feline patient,”Veterinary
Dermatology, vol. 15, pp. 9–10, 2004.
[14] J. H. Andersen, L. G. Hansen, and M. Pedersen, “Optimization
of solid phase extraction clean up and validation of quan-
titative determination of corticosteroids in urine by liquid
chromatography-tandem mass spectrometry,” Analytica Chim-
ica Acta, vol. 617, no. 1-2, pp. 216–224, 2008.
[15] F. K. Gło´wka, M. Karaz´niewicz, and E. Lipnicka, “RP-HPLC
method with fluorescence detection for determination of small
quantities of triamcinolone in plasma in presence of endoge-
nous steroids after derivatization with 9-anthroyl nitrile; phar-
macokinetic studies,” Journal of Chromatography B, vol. 839, no.
1-2, pp. 54–61, 2006.
[16] J. M. Lemus Gallego and J. Pe´rez Arroyo, “Determination of
prednisolone and the most important associated compounds in
ocular and cutaneous pharmaceutical preparations by micellar
electrokinetic capillary chromatography,” Journal of Chromatog-
raphy B, vol. 784, no. 1, pp. 39–47, 2003.
[17] S. Noe´, J. Bo¨hler, E. Keller, and A.W. Frahm, “Determination of
prednisolone in serum: method development using solid-phase
extraction andmicellar electrokinetic chromatography,” Journal
of Pharmaceutical and Biomedical Analysis, vol. 18, no. 3, pp.
471–476, 1998.
[18] H. Shibasaki, H. Nakayama, T. Furuta et al., “Simultaneous
determination of prednisolone, prednisone, cortisol, and cor-
tisone in plasma by GC-MS: estimating unbound prednisolone
concentration in patients with nephrotic syndrome during oral
prednisolone therapy,” Journal of Chromatography B, vol. 870,
no. 2, pp. 164–169, 2008.
[19] N. Shibata, T. Hayakawa, K. Takada, N. Hoshino, T. Minouchi,
and A. Yamaji, “Simultaneous determination of glucocorticoids
in plasma or urine by high-performance liquid chromatogra-
phy with precolumn fluorimetric derivatization by 9-anthroyl
nitrile,” Journal of Chromatography B, vol. 706, no. 2, pp. 191–
199, 1998.
[20] S. Tunn, G. Pappert, P. Willnow, and M. Krieg, “Multicentre
evaluation of an enzyme-immunoassay for cortisol determina-
tion,” Journal of Clinical Chemistry and Clinical Biochemistry,
vol. 28, no. 12, pp. 929–935, 1990.
[21] M. J. Del Sole, P. H. Sande, A. E. Felipe et al., “Characterization
of uveitis induced by use of a single intravitreal injection
of bacterial lipopolysaccharide in cats,” American Journal of
Veterinary Research, vol. 69, no. 11, pp. 1487–1495, 2008.
[22] R. Notari, Biopharmaceutics and Clinical Pharmacokinetics,
Marcel Dekker, New York, NY, USA, 1987.
[23] D. Perrier andM.Mayersohn, “Noncompartmental determina-
tion of the steady-state volume of distribution for any mode of
administration,” Journal of Pharmaceutical Sciences, vol. 71, no.
3, pp. 372–373, 1982.
[24] M. Gibaldi and D. Perrier, Pharmacokinetics, Marcel Dekker,
New York, NY, USA, 1982.
[25] J. D. Baggot, Principles of Drug Disposition: The Basis of
Veterinary Clinical Pharmacology, Saunders, Philadelphia, Pa,
USA, 1977.
[26] J. T. DiPiro, W. J. Spruill, R. A. Blouin et al., Concepts in
Clinical Pharmacokinetics, American Society of Health Systems
Pharmacists, Bethesda, Md, USA, 2005.
[27] H. G. Eichler and M. Mu¨ller, “Drug distribution. The forgotten
relative in clinical pharmacokinetics,” Clinical Pharmacokinet-
ics, vol. 34, pp. 95–99, 1998.
[28] C. N. J. McGhee, D. G.Watson, J. M.Midgley, M. J. Noble, G. N.
Dutton, and A. I. Fern, “Penetration of synthetic corticosteroids
into human aqueous humour,” Eye, vol. 4, no. 3, pp. 526–530,
1990.
[29] K.-Y. Chien, T.-T. Chen, J. Hsu et al., “Sub-maximal exercise
alters the prednisolone absorption pattern,” Journal of Phar-
macy and Pharmaceutical Sciences, vol. 13, no. 1, pp. 58–66, 2010.
[30] L. Shargel and A. Yu, Applied Biopharmaceutics & Pharmacoki-
netics, McGraw-Hill, New York, NY, USA, 2002.
[31] O. Weijtens, R. C. Schoemaker, A. F. Cohen et al., “Dex-
amethasone concentration in vitreous and serum after oral
administration,” American Journal of Ophthalmology, vol. 125,
no. 5, pp. 673–679, 1998.
[32] K. Hippalgaonkar, R. Srirangam, B. Avula, I. A. Khan, and
S. Majumdar, “Interaction between topically and systemically
coadministered P-glycoprotein substrates/inhibitors: effect on
vitreal kinetics,” Drug Metabolism and Disposition, vol. 38, no.
10, pp. 1790–1797, 2010.
[33] W. J. Tranquilli, J. C. Thurmon, and G. J. Benson, “Lumb and
Jones’ veterinary anesthesia,” inLumband Jones,W. J. Tranquilli,
J. C. Thurmon, and G. J. Benson, Eds., Williams and Wilkins,
Baltimor, Md, USA, 3rd edition, 1998.
[34] M. Goppelt-Struebe, D. Wolter, and K. Resch, “Glucocorti-
coids inhibit prostaglandin synthesis not only at the level of
phospholipase A2 but also at the level of cyclo-oxygenase/PGE
isomerase,” British Journal of Pharmacology, vol. 98, no. 4, pp.
1287–1295, 1989.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Journal of
Pharmaceutics
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Pain
Drug Delivery
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Advances in 
Pharmacological 
Sciences
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Anesthesiology
Research and Practice
ISRN 
Pharmaceutics
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Mediators
inflaMMation
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Antibiotics
International Journal of
Volume 2013
ISRN 
Medicinal 
Chemistry
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Medicinal Chemistry
International Journal of
ISRN 
Toxicology
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Toxins
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
 Autoimmune 
Diseases
Toxicology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Pharmacology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Emergency Medicine 
International
